STING-IN-13 

STING-IN-13 is a selective STING inhibitor. STING-IN-13 can effectively inhibit downstream signaling of the STING pathway and inhibit STING-mediated inflammation. STING-IN-13 has low toxicity and can be used to study STING-related inflammatory and autoimmune diseases^[1].

STING-IN-13 (Compound HY2) (30 μM) shows direct interaction with STING in RAW264.7 cells^[1].
STING-IN-13 (0.03 μM-0.3 μM, pre-treat for 1 h, then co-incubation for 2-4 h) effectively inhibits the downstream signaling of the STING pathway in THP1 and RAW264.7 cells induced by SR717 (HY-131454), and effectively reduces the production of inflammatory factors IFN-β and CXCL10^[1].
STING-IN-13 (0.4 μM-3.3 μM, 48 h) has excellent safety and low cytotoxicity in THP1 cells^[1].
STING-IN-13 (5 μM, pre-treat for 1 h, then treat for 2 h) specifically inhibits STING-driven IFNβ expression in THP1 cells without affecting the TLR pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

STING-IN-13 (10,20 mg/kg, i.p. one dose) improves survival rate, protects renal and liver functions, and reduces tubular damage and inflammatory cell infiltration in the Cisplatin (HY-17394) -induced AKI mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

377.36

C₁₉H₁₈F₃N₃O₂

O=C(NC1=CC=C(OCCCC(F)(F)F)C=C1)NC2=CNC3=CC=CC=C32

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Xue L, et al. Design, synthesis, and activity evaluation of novel STING inhibitors based on C170 and H151. Eur J Med Chem. 2025 Mar 19;290:117533.  [Content Brief]